Filter Results:
- Full text PDF available (6)
Publication Year
1988
2018
- This year (3)
- Last 5 years (8)
- Last 10 years (16)
Publication Type
Co-author
Journals and Conferences
Learn More
- Michele Cavo, Lucia Pantani, +27 authors Antonio Palumbo
- Blood
- 2012
In a randomized, phase 3 study, superior complete/near-complete response (CR/nCR) rates and extended progression-free survival were demonstrated with bortezomib-thalidomide-dexamethasone (VTD) versus… (More)
- Armando Santoro, Massimo Magagnoli, +9 authors Monica Balzarotti
- Haematologica
- 2007
BACKGROUND AND OBJECTIVES
Response to pre-transplant salvage chemotherapy remains the most important prognostic factor for outcome in refractory or relapsed Hodgkin's lymphoma. Results of a new… (More)
- Eduardo Nobile-Orazio, Fabrizia Terenghi, Claudia Giannotta, Francesca Gallia, Andrea Nozza
- Neurology
- 2009
- Jacques Bonnet, Ruth Mcpherson, +4 authors Jean Davignon
- Clinical therapeutics
- 2008
BACKGROUND
The major beneficial effect of statins- reducing the risk for coronary events-has primarily been ascribed to reductions in low-density lipoprotein cholesterol (LDL-C) but may in part be… (More)
- Carlo Castagnola, Andrea Nozza, Alessandro Corso, Carlo Bernasconi
- Haematologica
- 1997
BACKGROUND AND OBJECTIVE
In adult patients with acute myeloid leukemia (AML), central nervous system (CNS) involvement is a rare event and treatment has not yet been defined. Because there are no… (More)
- Alessandro Corso, Andrea Nozza, +4 authors Carlo Bernasconi
- Haematologica
- 1999
BACKGROUND AND OBJECTIVE
In multiple myeloma (MM) patients treated with conventional chemotherapy, the attainment and duration of a plateau phase seems to affect survival more than the degree of… (More)
- Luca Castagna, Stefania Bramanti, +11 authors Armando Santoro
- British journal of haematology
- 2009
This retrospective study evaluated whether early 2-[fluorine-18]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) after two cycles of salvage chemotherapy (PET2) could predict survival… (More)
- Antonio Palumbo, Sara Bringhen, +22 authors Mario Boccadoro
- Blood
- 2010
High-dose (200 mg/m(2), MEL200) and intermediate-dose melphalan (100 mg/m(2), MEL100) showed significant activity in myeloma. In a phase 3 study, 298 patients were randomly assigned to receive 2… (More)
- Luca Castagna, Massimo Magagnoli, +9 authors Armando Santoro
- American journal of hematology
- 2007
We designed a prospective study to evaluate the feasibility and efficacy of tandem high-dose chemotherapy (HDCT) in the treatment of refractory or relapsed Hodgkin's lymphoma (HL). Thirty-two… (More)
- Alexia Francesca Bertuzzi, Luca Castagna, +10 authors Armando Santoro
- British Journal of Cancer
- 2003
A total of 10 desmoplastic small round-cell tumour patients were treated by high-dose chemotherapy with stem cell support. After high-dose chemotherapy, no complete response conversion was obtained… (More)